Alliqua BioMedical (ALQA) saw its loss widen to $17.14 million, or $0.61 a share for the quarter ended Dec. 31, 2016. In the previous year period, the company reported a loss of $4.23 million, or $0.16 a share. On the other hand, adjusted net loss for the quarter narrowed to $4.84 million, or $0.17 a share from a loss of $5.26 million or $0.19 a share, a year ago. 

Revenue during the quarter grew 25.37 percent to $4.94 million from $3.94 million in the previous year period. Gross margin for the quarter expanded 538 basis points over the previous year period to 65.60 percent.

Operating loss for the quarter was $17.35 million, compared with an operating loss of $5.10 million in the previous year period.

"Our fourth quarter total revenue results were driven by strong growth in sales of our Biologics products, a continuation of the trends we have seen throughout the year in 2016," said David Johnson, chief executive officer of Alliqua BioMedical. “Our Biovance Human Amniotic Membrane Allograft was notably strong in the fourth quarter with growth of more than 200% year-over-year, and our second biologic product, Interfyl Human Connective Tissue Matrix, is demonstrating impressive commercial traction following its launch in the third quarter of 2016."

Alliqua BioMedical projects revenue to be in the range of $19.80 million to $20.70 million for financial year 2017.        

Debt comes down marginally
Alliqua BioMedical has recorded a decline in total debt over the last one year. It stood at $11.54 million as on Dec. 31, 2016, down 4.82 percent or $0.58 million from $12.13 million on Dec. 31, 2015. Short-term debt stood at $11.54 million as on Dec. 31, 2016. Total debt was 21.18 percent of total assets as on Dec. 31, 2016, compared with 13.51 percent on Dec. 31, 2015. Debt to equity ratio was at 0.36 as on Dec. 31, 2016, up from 0.23 as on Dec. 31, 2015.